Fig. 1From: Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFROverview of current molecular targets in advanced/metastatic non-small-cell lung cancer (NSCLC). Protein kinase inhibitors for NSCLC therapy, either approved or in advanced clinical trials, are shown in green boxes; antibodies against cytokine targets HGF asnd VEGF are gray. EGFR, MET and ALK are labeled with blue circles Back to article page